Trial Profile

A Phase II Adjuvant Study of GRANITE-001 in High-Risk Localized Tumors

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 12 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GRANITE 001 (Primary)
Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours
Focus Therapeutic Use
Sponsors Gritstone bio

Most Recent Events

05 Aug 2021 According to a Gritstone bio media release, the company expects to initiate this study in the first half of 2022.
06 May 2021 According to a Gritstone bio media release, the company expects to initiate this study in the second half of 2021.
24 Jun 2020 According to a Gritstone Oncology media release, the company announced that the company will host an investor teleconference and webcast on July 13, 2020 at 8:00 a.m. ET where phase 2 study plans will also be discussed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com